TELA Bio, Inc. TELA

Company Overview

TELA Bio, Inc. is a U.S.-based commercial-stage medical technology company focused on developing and marketing soft tissue reconstruction solutions used in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. The company operates within the medical devices and biologics sectors, with a primary emphasis on regenerative medicine and implantable surgical materials. Its products are designed to reinforce soft tissue while supporting tissue remodeling and preservation of patient anatomy. TELA Bio generates revenue primarily through sales of biologic and synthetic reinforced tissue matrices sold to hospitals and surgical centers.

The company’s principal product platform includes the OviTex line of reinforced tissue matrices and the OviTex PRS products used in plastic and reconstructive surgery applications. TELA Bio positions itself as a differentiated player by combining biologic materials with polymer reinforcement technology intended to improve durability while minimizing foreign material exposure compared with conventional synthetic mesh products. Founded in 2012 and headquartered in Pennsylvania, the company evolved from a development-stage regenerative medicine business into a publicly traded commercial enterprise following its initial public offering in 2019. Public disclosures in SEC filings and investor presentations indicate that the company’s growth strategy has centered on surgeon adoption, expanded clinical evidence generation, and broader commercial penetration in the U.S. surgical market.